Mydayis vs. Adderall: Key Differences
Mydayis and Adderall are both mixed amphetamine salt formulations, but Mydayis is a triple-bead extended-release formulation designed for up to 16 hours of effect and approved only for ages 13 and older, while Adderall XR (extended-release) provides approximately 12 hours of coverage and is approved for children as young as 6 years. 1
Duration of Action
The most clinically significant difference is duration:
- Mydayis: Provides symptom control for up to 16 hours post-dose, with demonstrated efficacy from 2-4 hours through 16 hours in clinical trials 1, 2
- Adderall XR: Provides symptom control for approximately 12 hours, with documented efficacy at 4 and 12 hours post-dose 3
This extended duration makes Mydayis particularly useful for patients requiring late afternoon and evening symptom coverage, addressing a common gap in standard extended-release formulations 2.
Formulation Technology
- Mydayis: Uses a triple-bead delivery system with three distinct release phases to achieve its extended 16-hour duration 1, 2
- Adderall XR: Uses a dual-bead system combining immediate-release and delayed-release beads for 12-hour coverage 3
Approved Age Groups
This is a critical prescribing distinction:
- Mydayis: FDA-approved only for ages 13 years and older (adolescents and adults). Explicitly NOT approved for children 12 years and younger 1
- Adderall XR: FDA-approved for ages 6 years and older, including younger children 4, 5
Dosing
Mydayis 1:
- Starting dose: 12.5 mg once daily in the morning
- Available doses: 12.5 mg, 25 mg, 37.5 mg, 50 mg
- Maximum adult dose: 50 mg/day
- Single morning dose only due to 16-hour duration
- Typical starting dose: 10 mg once daily
- Dose range: 10-40 mg/day in adolescents; 20-60 mg/day in adults
- Single morning dose
Clinical Efficacy
Both medications demonstrate robust efficacy as first-line ADHD treatments 6:
- Mydayis: Showed statistically significant improvements in ADHD-RS-IV scores across all approved doses (12.5-50 mg) with effect sizes around 0.8, with the unique advantage of maintaining efficacy through evening hours 1, 2
- Adderall XR: Demonstrated mean effect size of 0.8 with significant symptom reduction maintained over 24 months of treatment 3, 5
Pharmacokinetics
Mydayis produces approximately 21-31% higher peak concentrations (Cmax) and total exposure (AUC) in adolescents (ages 13-17) compared to adults at equivalent doses, requiring careful dose titration in younger patients 1.
Common Pitfalls
- Age restriction violation: Do not prescribe Mydayis to children under 13 years—use Adderall XR or other approved formulations instead
- Timing errors: Both must be taken in the morning upon waking; Mydayis especially cannot be taken later due to its 16-hour duration causing insomnia 1
- Missed dose management: If a dose is missed, do NOT take later in the day or double the next dose—skip and resume normal schedule 1
- Duration expectations: Patients switching from Adderall XR to Mydayis should be counseled about the extended 16-hour coverage to avoid evening rebound concerns
Safety Profile
Both medications share similar adverse effect profiles typical of amphetamine stimulants 6, 1:
- Decreased appetite (most common)
- Insomnia
- Headache
- Increased blood pressure and heart rate
- Abdominal pain
Both are Schedule II controlled substances with abuse potential and require the same cardiovascular and psychiatric monitoring 1.
Clinical Decision-Making
Choose Mydayis when:
- Patient is ≥13 years old
- Extended coverage into evening hours is needed (homework, after-school activities, evening family functioning)
- Patient has documented afternoon/evening symptom breakthrough on 12-hour formulations
Choose Adderall XR when:
- Patient is 6-12 years old (Mydayis not approved)
- 12-hour coverage is sufficient
- Cost is a significant factor (Adderall XR has generic availability)